testiculus
Active Member
Old study that looked at exogenous estrogen (among other things) in men targeted at reducing mortality due to cardiac events:
The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group.
The purpose of the Coronary Drug Project, a national collaborative study, is to evaluate long-term effects of several drug regimens influencing lipid metabolism, compared with placebo, in men originally aged 30-64 years who had recovered from 1 or more episodes of myocardial infarction. 53 clinical centers recruited 8341 patients from 1966-1969; the men were randomly assigned to the project's 6 groups. 2 of the study regimens - 5.0 mg/day of estrogen (ESG2) and 6.0 mg/day of dextrothyroxine (DT4) were discontinued in 1970 and 1971, respectively, due to trends indicative of adverse effects. As of February 1, 1973, with an average followup of 56 months, data on the 2.5 mg/day estrogen group (ESG1) indicated no evidence of an overall positive therapeutic effect in terms of the project's primary end point, mortality from all causes.
The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group.
The purpose of the Coronary Drug Project, a national collaborative study, is to evaluate long-term effects of several drug regimens influencing lipid metabolism, compared with placebo, in men originally aged 30-64 years who had recovered from 1 or more episodes of myocardial infarction. 53 clinical centers recruited 8341 patients from 1966-1969; the men were randomly assigned to the project's 6 groups. 2 of the study regimens - 5.0 mg/day of estrogen (ESG2) and 6.0 mg/day of dextrothyroxine (DT4) were discontinued in 1970 and 1971, respectively, due to trends indicative of adverse effects. As of February 1, 1973, with an average followup of 56 months, data on the 2.5 mg/day estrogen group (ESG1) indicated no evidence of an overall positive therapeutic effect in terms of the project's primary end point, mortality from all causes.
